These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36302245)

  • 1. Severe cutaneous reaction to the messenger RNA (mRNA) BNT162b2 (Pfizer-BioNTech) vaccine.
    Sapsford S; Wood B
    N Z Med J; 2022 Oct; 135(1564):72-76. PubMed ID: 36302245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Unusual Presentation Of Steven-Johnson Syndrome After Bnt162b2 Covid-19 Vaccination.
    Patel R; Lu V
    J Ayub Med Coll Abbottabad; 2023; 35(1):180-181. PubMed ID: 36849405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the adverse events of Oxford-AstraZeneca, Pfizer-BioNTech, Moderna, and Johnson and Johnson COVID-19 vaccination on Guillain-Barré Syndrome.
    Meo SA; Shaikh N; Abukhalaf FA; Meo AS
    Sci Rep; 2024 Aug; 14(1):18767. PubMed ID: 39138276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral lichen planus arising after BNT162b2 mRNA COVID-19 vaccine: report of 2 cases.
    Raccampo L; Sembronio S; Tel A; Cacitti V; Robiony M
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2022 Sep; 134(3):e54-e57. PubMed ID: 35851250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Author's reply to correspondence.
    Ripabelli G; Salzo A; Tamburro M
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168947. PubMed ID: 36655383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine.
    Luo A; Oakley A
    Australas J Dermatol; 2022 Aug; 63(3):e247-e250. PubMed ID: 35607272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
    Walton M; Pletzer V; Teunissen T; Lumley T; Hanlon T
    Drug Saf; 2023 Sep; 46(9):867-879. PubMed ID: 37556109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxic epidermal necrolysis after first dose of Pfizer-BioNTech (BNT162b2) vaccination with pharmacogenomic testing.
    Siripipattanamongkol N; Rattanasak S; Taiyaitieng C; Inthajak Y; Kuawatcharawong N; Sukasem C; Tempark T
    Pediatr Dermatol; 2022 Jul; 39(4):601-605. PubMed ID: 36000937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombotic events following the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) in Aotearoa New Zealand: A self-controlled case series study.
    Walton M; Tomkies R; Teunissen T; Lumley T; Hanlon T
    Thromb Res; 2023 Feb; 222():102-108. PubMed ID: 36634464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extensive Cerebral Venous Sinus Thrombosis (CVST) After the First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine without Thrombotic Thrombocytopenia Syndrome (TTS) in a Healthy Woman.
    Alhashim A; Hadhiah K; Al Khalifah Z; Alhaddad FM; Al ARhain SA; Bin Saif FH; Abid A; Al Gamdi O; Alsulaiman F; AlQarni M
    Am J Case Rep; 2022 Feb; 23():e934744. PubMed ID: 35136010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curbing COVID-19 Vaccine Hesitancy from a Dermatological Standpoint: Analysis of Cutaneous Reactions in the Vaccine Adverse Event Reporting System (VAERS) Database.
    Falotico JM; Desai AD; Shah A; Ricardo JW; Lipner SR
    Am J Clin Dermatol; 2022 Sep; 23(5):729-737. PubMed ID: 35931925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence.
    Mungmunpuntipantip R; Wiwanitkit V
    Hum Vaccin Immunother; 2022 Dec; 18(7):2149015. PubMed ID: 36404633
    [No Abstract]   [Full Text] [Related]  

  • 15. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273.
    Teo SP
    J Pharm Pract; 2022 Dec; 35(6):947-951. PubMed ID: 33840294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
    Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
    MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of BNT162b2 Messenger RNA Vaccine and ChAdOx1 Adenovirus Vector Vaccine on Deaths From COVID-19 in Adults Aged ≥70 Years.
    Lopez Bernal J; Andrews N; Gower C; Stowe J; Tessier E; Simmons R; Ramsay M
    Clin Infect Dis; 2024 Feb; 78(2):349-351. PubMed ID: 37758203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2.
    Schroeder JW; Gamba C; Toniato A; ; Rongioletti F
    Clin Dermatol; 2022; 40(5):591-594. PubMed ID: 35550918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.